Trifarotene is the most recent topical retinoid to receive regulatory approval for treatment of acne; it has a very low systemic absorption, making it well suited for treatment of large skin areas. Clinical trials of trifarotene included evaluations of both facial and truncal acne and showed efficacy in both areas.

In patients at increased risk for atrophic acne scarring, trifarotene cream significantly reduces the development of scars as well as improves appearance of existing atrophic scars.